April 9 (Reuters) - Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by Summit Therapeutics' executive Ankur Dhingra. (Reporting by Pritam Biswas in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.685 USD | -20.47% | +156.95% | +232.76% |
May. 31 | Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday | MT |
May. 31 | Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
104.3 USD | +3.20% | -2.07% | 16.61B | ||
8.685 USD | -20.47% | +156.95% | 6.1B | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+232.76% | 6.1B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor